Bronchial carcinoid in anomalous right upper bronchus: a "patient-tailored" bronchoplasty resection technique
Petrella F., Mariolo AV., Guarize J., Donghi S., Girelli L., Rizzo S.
Case Report / Series, published in J Vis Surg (2018) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Case Report / Series
- Journal
- J Vis Surg (2018)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 29780727
- PMCID
- PMC5945899
- DOI
- 10.21037/jovs.2018.03.11
- Citations
- 1
Abstract (original English)
Bronchial carcinoids (BC) are indolent neuroendocrine tumors (NET) that are classified as malignant because they can locally infiltrate and metastasize. Resection is the primary treatment for most localized carcinoid tumors, with lung parenchymal-sparing surgery the favoured objective for patients with central airway tumors. Sleeve bronchoplasty techniques are complex surgical procedures defined as parenchyma-saving because they allow a radical resection with tumor-free margins while preserving the maximum amount of parenchyma. They are mainly indicated for tumors arising at the origin of a lobar bronchus, precluding simple lobectomy but not infiltrating so far as to require pneumonectomy. We describe a case of typical bronchial carcinoid of an anomalous right upper bronchus requiring a "patient-tailored" bronchoplasty technique. The surgical aspects and preoperative work-up are discussed.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.